CVS HEALTH Corp purchased a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the third quarter, HoldingsChannel.com reports. The firm purchased 10,000 shares of the exchange traded fund’s stock, valued at approximately $1,577,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of XBI. Bank of America Corp DE lifted its holdings in SPDR S&P Biotech ETF by 13.3% in the 1st quarter. Bank of America Corp DE now owns 14,518,027 shares of the exchange traded fund’s stock worth $1,854,388,000 after buying an additional 1,700,851 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in shares of SPDR S&P Biotech ETF by 145.7% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 314,224 shares of the exchange traded fund’s stock worth $49,726,000 after buying an additional 186,314 shares during the last quarter. Annex Advisory Services LLC grew its position in shares of SPDR S&P Biotech ETF by 4.6% in the 3rd quarter. Annex Advisory Services LLC now owns 266,485 shares of the exchange traded fund’s stock worth $42,019,000 after buying an additional 11,723 shares during the last quarter. Moss Adams Wealth Advisors LLC purchased a new position in shares of SPDR S&P Biotech ETF during the third quarter valued at approximately $30,841,000. Finally, Sivik Global Healthcare LLC increased its stake in shares of SPDR S&P Biotech ETF by 20.0% during the third quarter. Sivik Global Healthcare LLC now owns 180,000 shares of the exchange traded fund’s stock valued at $28,382,000 after buying an additional 30,000 shares during the period.
SPDR S&P Biotech ETF Stock Up 0.8%
Shares of SPDR S&P Biotech ETF stock opened at $156.31 on Thursday. The company has a market cap of $10.55 billion, a PE ratio of 11.47 and a beta of 0.87. The business has a 50 day moving average of $154.82 and a 200 day moving average of $142.69. SPDR S&P Biotech ETF has a 52 week low of $111.11 and a 52 week high of $169.89.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Featured Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
